The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965), AHA-supported legislation that would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. Previously passed by the Energy and Commerce Committee, the bill could next move to the floor.
 
In other action yesterday, the Judiciary Committee approved bipartisan bills to strengthen the Federal Trade Commission’s ability to challenge anticompetitive pay-for-delay agreements in court (H.R. 2375); reduce incentives for brand name drug makers to interfere with the regulatory approval of generics and biosimilars (H.R. 2374); and require the FTC to study competition in the drug supply chain (H.R. 2376).

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health today passed the No Surprises Act (H.R. 3630), bipartisan legislation that would prohibit balance billing…
Headline
The House Energy and Commerce Subcommittee on Health tomorrow is scheduled to mark up 10 health-related bills, including the No Surprises Act — bipartisan…
Headline
The Centers for Medicare…
Blog
Women in rural areas face unique maternal health care challenges, including hospital closures or lack of obstetric services. In this AHA Stat Blog, Jay Bhatt,…
Headline
The Senate Judiciary Committee today passed four bills aimed at lowering prescription drug costs and increasing competition.
Headline
Hospitals spend close to $360 million each year to manage drug shortages, according to a study released this week by Vizient Inc.